As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Belgian industry association Medaxes has appointed a new board at the same time as revealing plans for a biosimilars awareness day in April, following in the footsteps of a recent initiative focused on generics.

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.

Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.